Logo image of MDCX

MEDICUS PHARMA LTD (MDCX) Stock Fundamental Analysis

USA - NASDAQ:MDCX - CA58471K2020 - Common Stock

2.72 USD
-0.05 (-1.81%)
Last: 9/22/2025, 7:16:06 PM
2.77 USD
+0.05 (+1.84%)
After Hours: 9/22/2025, 7:16:06 PM
Fundamental Rating

1

MDCX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. While MDCX seems to be doing ok healthwise, there are quite some concerns on its profitability. MDCX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

MDCX had negative earnings in the past year.
MDCX had negative earnings in each of the past 5 years.
MDCX had a negative operating cash flow in each of the past 5 years.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

MDCX has a worse Return On Assets (-195.00%) than 90.33% of its industry peers.
With a Return On Equity value of -319.45%, MDCX is not doing good in the industry: 71.93% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

MDCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, MDCX has more shares outstanding
MDCX has more shares outstanding than it did 5 years ago.
MDCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

MDCX has an Altman-Z score of 2.64. This is not the best score and indicates that MDCX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of MDCX (2.64) is better than 69.52% of its industry peers.
MDCX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MDCX (0.07) is worse than 62.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 2.64
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

MDCX has a Current Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.73, MDCX is not doing good in the industry: 67.10% of the companies in the same industry are doing better.
A Quick Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.73, MDCX is not doing good in the industry: 65.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

MDCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.18%, which is quite impressive.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MDCX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.61% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.49%
EPS Next 2Y25.21%
EPS Next 3Y16.61%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly Revenue VS EstimatesMDCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

0

4. Valuation

4.1 Price/Earnings Ratio

MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

MDCX's earnings are expected to grow with 16.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.21%
EPS Next 3Y16.61%

0

5. Dividend

5.1 Amount

MDCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MEDICUS PHARMA LTD

NASDAQ:MDCX (9/22/2025, 7:16:06 PM)

After market: 2.77 +0.05 (+1.84%)

2.72

-0.05 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)N/A N/A
Inst Owners10.3%
Inst Owner ChangeN/A
Ins Owners12.09%
Ins Owner Change11.39%
Market Cap55.27M
Analysts82.22
Price Target20.06 (637.5%)
Short Float %2.93%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.45%
Min EPS beat(2)-76.47%
Max EPS beat(2)-60.43%
EPS beat(4)1
Avg EPS beat(4)-54%
Min EPS beat(4)-118.27%
Max EPS beat(4)39.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-6.67%
EPS NQ rev (3m)-26.32%
EPS NY rev (1m)-6.73%
EPS NY rev (3m)-58.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 15.83
P/tB 15.83
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z 2.64
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
EPS Next Y39.49%
EPS Next 2Y25.21%
EPS Next 3Y16.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-320.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.43%
OCF growth 3YN/A
OCF growth 5YN/A